진행성 직장암에서 수술 후 보조 치료법으로 5-Fluorouracil의 경정맥 투여와 Doxifluridine의 경구투여에 대한 전향적 임의 비교 연구
Prospective Randomized Trials Comparing Intravenous 5-Fluorouracil and Oral Doxifluridine as a Postoperative Adjuvant Treatment for Advanced Rectal Cancer
김남규, 이강영, 민진식, 박재균, 윤성현, 노재경,
소속 상세정보
김남규 ( Kim Nam-Kyu )
연세대학교 의과대학 외과학교실
이강영 ( Rhee Kang-Young )
연세대학교 의과대학 외과학교실
민진식 ( Min Jin-Sik )
연세대학교 의과대학 외과학교실
박재균 ( Park Jea-Kun )
연세대학교 의과대학 외과학교실
윤성현 ( Yun Seong-Hyeun )
연세대학교 의과대학 외과학교실
노재경 ( Roh Jae-Kyung )
연세대학교 의과대학 암센터
KMID : 0371320010600020195
Abstract
Purpose: Intravenous 5-Fluorouracil (5-FU) and oral doxifluridine were compared with respect to therapeutic efficacy, drug toxicity, and quality of life to clarify the efficiency of oral doxifluridine.
Methods: One hundred sixty-six (166) patients who underwent a curative resection for TNM stage II and III rectal cancer between Oct. 1997 and Feb. 1999 were randomized to receive intravenous 5-FU (450 mg/m2/day) or oral doxifluridine (700 mg/m2/day) in combination with leucovorin (20 mg/m2/day). 5-FU was infused intravenously 5 consecutive days per month for a total of 12 cycles (IV arm, N=74) in one group, and doxifluridine was given orally daily for 3 weeks with a rest of 1 week for a total of 12 cycles (Oral arm, N=92). Drug toxicity and quality of life were observed. Quality of life was scored according to twenty-two daily activity items (good,＞71, fair,53≤and＜70, poor,≤52).
Results: There was no significant difference in the mean age, sex, TNM stage distribution, or type of operation between the two groups (＞0.05). Mean number of chemotherapy cycles was 6.5±3.7 (IV arm) vs 7.2±4.3 (Oral arm). The recurrence rate was 9/74 (12.1%) in IV arm and 6/92 (6.5%) in oral arm (P=0.937). Local recurrence was 2/74 (stage III; 2.7%) in IV arm and 1/92 (stage II; 1.1%) in oral arm. Systemic recurrence was 7/74 (Stage III; 9.4%) in IV arm and 5/92 (Stage III; 5.4%) in oral arm. Toxicity pro-files are as follows: Leukopenia (30/74, 17/92) and alopecia (21/74, 13/92) were more common in IV arm than in oral arm, and the difference was statistically significant. Diarrhea was more common in oral arm. The quality of life score was better at 1 month (19.5%, 49%) and at 2 months (47%, 72%) in the oral arm group (＜0.05).
Conclusion: Oral Doxifluridine with leucovorin as a postoperative adjuvant therapy shows a therapeutic efficacy comparable to the intravenous 5-FU regimen and has a high quality of life. The oral regimen also can be safely given with an appropriate toxicity and tolerability.
키워드
직장암;수술 후 보조치료;5-FU;Doxifluridine
Rectal cancer;Postoperative adjuvant treatment;5-FU;Doxifluridine
원문 및 링크아웃 정보
등재저널 정보